Hypertrophic scarring (HS) is a common fibro-proliferative disorder that typically follows burns and other injuries involving the deep dermis which is predominantly occupied by the overgrown dermal fibroblasts and the excessive extracellular matrix (ECM) 1 . The formation and development of HS are closely accompanied with the extravagant secretion of various cytokines, such as TGF-β 2, 3 , which is suggested to stimulate the growth of granulation tissues and promote the transformation of fibroblasts into proliferative and more contractile myofibroblast-type cells 4 , which is identified by the expression of α -smooth muscle actin (α -SMA) and in turn secretes abundant ECM proteins, including fibrous collagens that cause scar formation and organ fibrosis. However, the existing therapies for HS are rather restricted largely because of the quite limited understanding of the underlying mechanism and involved signaling pathway.
Focal adhesion kinase (FAK) and Src are two important non-receptor tyrosine kinases that have been indicated to be involved in the process of would healing [5] [6] [7] . FAK is found at focal adhesions, the sites of integrin clustering at the cell-ECM interface, where it provides both signaling and scaffolding functions 8 . FAK is activated in a range of tumor cells, and its increased activity correlates with the malignancy and invasiveness of various tumors 9, 10 . Recent studies have implied FAK as a central mediator of fibrogenesis, and highlighted this kinase as a potential therapeutic target in fibrotic diseases 11 , for instance, the inhibition of FAK might represent a novel therapy for scarring disorders 12 .
The cellular form of the Src gene (c-Src) is the first proto-oncogene that was first discovered in the vertebrate genome in 1970s 13 . The coding product of c-Src is Src and its activity is regulated by tyrosine phosphorylation at two different residues with opposing effects. Phosphorylation at Tyr 529 deactivates Src, while phosphorylation at Tyr 416 results in Src activation 14 . Recent studies have showed that Src was activated in cells along the
The functional protein complex FAK-Src is activated in hypertrophic scar. FAK and Src were known to form a functional protein complex in various cells and tissues 18 . In this study, we found FAK was structurally associated with Src in both ND (Fig. 4A) and NF (Fig. 4B ), while their interaction was remarkably induced by ~2-or ~4-fold in HD (Fig. 4A) and HF (Fig. 4B) , respectively. Dual-labelled immunofluorescence analysis showed that the co-localization (as shown in orange in merged images) of FAK with Src was much stronger in HD (lower panel in Fig. 4C ) than that in ND (upper panel in Fig. 4C ). These results support the notion that FAK and Src could form FAK-Src protein complex under both normal and pathological skin conditions by protein-protein interaction. In addition, the differential FAK-Src interaction between normal skin and hypertrophic scar as our results shown may suggest that FAK-Src complex is crucial in the regulation of scar formation and progression. (Fig. 5A,H (Fig. 6A-E) , further demonstrating the effective transfection in vivo. H&E staining was then conducted to observe the effect of single or simultaneous transfection with FAK and/or Src mutants on extracellular matrix deposition. Results revealed that scar tissue transfected with empty vector showed excessive ECM deposition (Fig. 6F) , which is consistent with the pathological feature of hypertrophic scar. Single transfection of FAK Y407F or Src Y529E ameliorated ECM deposition only to some extent (~25%) (Fig. 6F) , while co-transfection with these two mutants remarkably reduced ECM deposition by ~60% (Fig. 6F) . Masson staining has been commonly used for detecting collagens in various tissues. In this study we performed Masson staining to observe collagen expression and its arrangement in scars after transfection of various constructs. Results revealed that scar tissue transfected with empty vector exhibited massive and disordered collagen fibers (Fig. 6G) . Single transfection of FAK Y407F or Src Y529E ameliorated collagen arrangement only to some extent (Fig. 6G) , while co-transfection of these two mutants remarkably improved the texture of scar tissue, exhibiting significantly lightened collagen staining and more organized arrangement (Fig. 6G) .
Simultaneous deactivation of FAK and Src by co-overexpressing FAK and Src mutants significantly down-regulates the expression of
Inhibiting the formation of FAK-Src complex by glabridin reduces ECM protein expression and improves collagen fiber arrangement. Glabridin, a chemical that was found able to block the formation of FAK-Src complex and reduced the aggressiveness of cancer cells 17 , was employed in the study to further verify if it would also affect the pathogenesis of hypertrophic scar. Immunoblotting results showed that glabridin deactivated both FAK and Src in hypertrophic scar fibroblasts as demonstrated by the down-regulated p-FAK-Tyr 407 and p-Src-Tyr 416 protein levels, also the up-regulated p-Src-Tyr 529 level (Fig. 7A ). Co-immunoprecipitation revealed glabridin significantly reduced the association between FAK and Src in HS fibroblasts (Fig. 7B ). In addition, glabridin remarkably decreased the three major ECM protein Col I, Col III and a-SMA levels in HS fibroblasts (Fig. 7C ). When glabridin was used to treat HS tissue, it induced a significant reduction in ECM deposition ( Fig. 7D ) and made collagen fiber more arranged (Fig. 7E ). These findings collectively further suggested that disruption of FAK-Src complex probably through the deactivation of FAK and Src would improve HS pathology.
Discussion
Hypertrophic scar is pathologically a significant skin fibrotic disease and the major characteristics of HS are the over-proliferation and activation of dermal fibroblasts, as well as the metabolic disorder of collagen-based ECM proteins 19 . Statistically, the incidence of HS ranges from 40~70% following surgery, and up to 91% following burn injury 7 . However, there is currently no effective therapeutically relevant targets for HS treatment largely due to the undefined molecular mechanism.
With the development of molecular biology, more and more protein kinases have been discovered and identified as drug targets to cure diseases, such as Src, FAK, and so on. Src has been involved in various cellular signaling events such as cell proliferation, migration, adhesion to ECM, as well as tumorigenesis. The inhibition of c-Src family was found to suppress the proliferation and migration of dermal fibroblasts induced by TGF-β 1, restrain the enhanced expression of α -SMA and the activation of FAK 20 . Moreover, the prohibited activation of fibroblasts and macrophages could further repress scar formation. Src integrates its activity into intracellular signaling networks by either phosphorylation at Tyr 416 , dephosphorylation at Tyr 529 , or through its substrates including FAK 21, 22 . FAK is another significant non-receptor protein tyrosine kinase which is expressed ubiquitously with essential roles in cell proliferation and migration. FAK has been implicated in HS formation and development. A recent study has shown that FAK was activated after cutaneous injury 23 , and the fibroblast-specific FAK knockout mice have substantially less inflammation and fibrosis than control mice in a model of hypertrophic scar formation 23 . The phosphorylation of FAK at Tyr 407 or Tyr 397 is normally required for FAK activation and various FAK-mediated cell behaviors 24 . In this study, we have identified that FAK and Src were significantly activated in HS vs. NS both in vivo (Fig. 1 ) and in vitro (Fig. 2) , indicated by the up-regulated p-FAK-Tyr 407 and p-Src-Tyr 529 protein levels, as well as the down-regulated p-Src-Tyr 529 level, suggesting the involvement of the activation of these two kinases in HS pathogenesis.
Would healing as well as subsequent scar formation is a process that recruits multiple cell types and various cytokines, such as TGF-β . Our results showed that FAK and Src were significantly activated after TGF-β 1 stimulation in normal skin-derived fibroblasts (Fig. 3) , further confirming that FAK and Src are involved in TGF-β -mediated signaling pathway in HS pathogenesis.
FAK and Src have been found to trigger the downstream signaling by forming a functional protein complex that is involved in various cellular events, including tumor growth and metastasis, as well as the control of cell shape and focal contact turnover during cell motility. The formation of FAK-Src complex commences with the activation of Src, the activated Src then trans-phosphorylated the kinase domain of FAK, which in turn bands to Src and forms the FAK-Src signaling complex. Our results showed that the interaction between FAK and Src assessed by co-immunoprecipitation (Fig. 4A,B) and their association visualized by dual-labelled immunofluorescence (Fig. 4C) were remarkably enhanced in HS compared to those in NS.
Since HS is a pathologically fibro-proliferative disorder of dermal wound healing characterized by excessive ECM accumulation, the exaggerated deposition and attenuated degradation of type I and type III collagens are the major cause during HS formation. Thus, based on above findings, we were eager to reveal if the abundant collagen deposition could be effectively improved by manipulating the phosphorylated status of FAK and/ or Src? Combining site-directed mutagenesis and gene overexpression techniques with FAK Tyr 407 replaced by non-phosphorylatable phenylalanine (F) and Src Tyr 529 replaced by phosphomimetic mutant glutamate (E), our results revealed that only simultaneous suppression of FAK activation by overexpressing FAK Y407F mutant and Src activation by overexpressing Src Y529E mutant could obviously down-regulate the expression levels of both Col I (Fig. 5A,F) and Col III (Fig. 5A,G) , reduced ECM accumulation (Fig. 6F) , and ameliorated collagen arrangement (Fig. 6G) , suggesting the synergistic action of FAK and Src on HS pathogenesis.
Src inhibition was found to suppress the accumulation of myofibroblasts and macrophages in the healing wound, and reduce the formation of hypertrophic scar after wound closing in a rabbit ear scar model, without delaying the wound closing process 20 . Our results showed that although the single deactivation of Src by overexpressing phosphomimetic mutant Src Y529E did not affect the protein expression of Col I (Fig. 5A,F) and α -SMA (Fig. 5A,H) vs. control (empty vector), it significantly reduced Col III level (Fig. 5A,G) , and slightly alleviated ECM deposition (Fig. 6F ) and improved the collagen fiber arrangement (Fig. 6G) .
The inhibition of FAK was found to effectively reduce α -SMA expression in human fibroblasts and scar formation in vivo 23 . FAK was also deactivated in xiamenmycin-induced inhibition of profibrotic effects 25 . A recent study showed that FAK RNAi in HS fibroblasts decreased the expression of TGF-β and α -SMA, inhibited cell proliferation, and reduced collagen synthesis 26 . Our results showed that the single deactivation of FAK by overexpressing the non-phosphorylatable mutant FAK Y407F slightly but significantly down-regulated Col III expression vs. control (empty vector) (Fig. 5A,G) , mildly improved collagen fiber arrangement (Fig. 6G ) and alleviated ECM deposition (Fig. 6F) . However, this did not affect α -SMA level (Fig. 5A,H) , even more, it induced a surge of Col I level (Fig. 5A,F) . In keloid, another kind of skin scar, the distribution of focal adhesion complex observed by FAK immunofluorescence staining was different from that in control fibroblasts 27 , suggesting FAK might play a general role in skin fibrotic diseases. Moreover, in addition to well-established roles of Src in tumorigenesis, Src performs a proinflammatory function by stimulating intracellular signal transduction, leading to acute inflammatory responses, which is one of the key steps in would healing process. It is likely that the interplay between FAK-Tyr 407 and Src-Tyr 529 in regulating HS fibrosis may involve other yet to be identified regulatory partners, such as c-Yes, In H&E staining, the cytoplasm and extracellular matrix, such as collagens, were stained with eosin and shown in pink, while the nuclei were counterstained with hematoxylin and shown in blue. Scale bar = 100 μ m. The relative density of ECM deposition was analyzed by Image J software with the value in pcDNA3.1(+) group arbitrarily set as 1. Each bar represents a mean ± SD of n = 4.
* P < 0.05, ** P < 0.01 vs. pcDNA3.1(+) group. (G) In Masson staining, collagen fibers were shown in blue, the cytoplasm was shown in pink, whereas nuclei were shown in dark blue. The arrangement of collagen fiber in each treatment group was observed. Scale bar = 100 μ m. The relative density of collagen deposition was analyzed by Image J software with the value in pcDNA3.1(+) group arbitrarily set as 1. Each bar represents a mean ± SD of n = 4. MAPKs. Further investigation is warranted to identify additional phosphorylation events and the signaling inputs from downstream molecules that are involved. In summary, this report demonstrates that the involvement of FAK/Src activation in HS pathogenesis, which further results in a de-association of FAK-Src complex, produces synergistic effects on regulating ECM deposition and collagen arrangement. These findings thus suggest FAK-Src complex as a potential molecular target, and disrupting FAK-Src association by manipulating FAK/Src activation status might be an effective method to treat HS or related fibrotic diseases. Antibodies. All antibodies were obtained commercially and the appropriate working dilutions are listed in Table 1 .
Cell culture and treatment. Hypertrophic scar and surrounding normal skin tissues were obtained from six patients (age ranges from 18-to 45-year old) undergoing plastic surgery between Jun 2013 to Jun 2014 in Department of Burns and Cutaneous Surgery in Xijing Hospital (Xi'an, China). Before the experiment, all patients were informed about the purpose and procedures of the study and voluntarily agreed to provide both scar and normal skin tissues. Written consent was obtained from all participants, and all protocols were approved by the Ethics Committee of Xijing Hospital, which is affiliated with the FMMU. Patients received no treatment before skin excision. The dermal portion from scar and normal skin was minced and incubated in a solution of collagenase type I (Sigma-Aldrich, St. Louise, MO) at 0.1 mg/ml at 37 °C for 3 h to isolate fibroblasts. Cells were then pelleted and grown in Dulbecco's modified Eagle's medium (DMEM) (Gibco, Grand Island, NY) supplemented with 10% fetal calf serum (Gibco), 100 U/ml penicillin and 100 U/ml streptomycin, and cultured at 37 °C in a 5% (v/v) CO 2 humidified atmosphere. Normal skin-derived fibroblasts with 70~80% confluence were incubated for 12 h in serum-depleted medium and then treated with TGF-β 1 at 5 ng/ml (PeproTech, Rocky Hill, NJ). 24 h thereafter, total proteins from fibroblasts in each sample were prepared for western blot analysis. Glabridin was purchased from Dalian Meilun Biotechnology Co. Ltd. (Dalian, China. Cat# 59870-68-7, Lot# N0706AS), dissolved in DMSO and used at 100 μ M as final working concentration to treat either HS fibroblasts or tissues.
Western blot analysis. Tissues or fibroblasts were washed with ice-cold phosphate-buffered saline (PBS) and lysed using RIPA buffer supplemented with protease and phosphatase inhibitor mixtures (Heart Biological Technology Co. Ltd., Xi'an, China) on ice. Lysates were separated by centrifugation at 4 °C and 14000 × g for 10 min. Protein concentration was determined by BCA assay (Pierce, Rockford, IL). 50 μ g total protein in each sample was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto PVDF membranes (Millipore, Bedford, MA). After blocking with 5% non-fat milk, membranes were incubated with specific antibody at appropriate dilutions as listed in Table 1 . On the next day, membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibody at 1:2000 dilution at 37 °C for 1 h. Then the immunoreactive proteins were visualized by using ECL western blotting detection reagents (Millipore, Billerica, MA) and detected by using MultiImage Light Cabinet Filter Positions (Alpha Innotech, San Leandro, CA).
Co-immunoprecipitation (Co-IP).
Lysates from normal skin and hypertrophic scar tissues or their corresponding fibroblasts were prepared in immunoprecipitation (IP) lysis buffer (10 mM Tris, 0.15 M NaCl, 1% NP-40, and 10% glycerol, pH 7.4 at 22 °C) supplemented with protease and phosphatase inhibitor cocktails (Sigma-Aldrich) according to the manufacturer's instructions as described earlier 28 . 500 μ g tissue lysates or 300 μg fibroblast lysates for each sample were first pre-cleaned with 2 μ g normal rabbit IgG and incubated for 1 h before being precipitated with 10 ml protein A/G agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h, then the supernatant was collected by centrifuging at 1000 × g for 5 min. This pre-cleaning step removed non-specific interacting proteins from lysates. Thereafter, the obtained lysates were incubated with 2 μ g normal rabbit IgG as negative control or specific rabbit anti-Src antibody for Co-IP on a Labnet Mini LabRoller Rotator (Labnet, Edison, NJ) at 4 °C overnight, to be followed by the incubation with 20 ml protein A/G agarose beads to extract the immunocomplexes. Thereafter, beads were washed with IP lysis buffer three times and the immunocomplexes were extracted in SDS sample buffer at 100 °C followed by immunoblot analysis.
Immunohistochemistry. Normal skin and hypertrophic scar tissues were fixed in 10% neutral buffered formalin solution overnight, then embedded in paraffin and cut at 4-μ m thickness. Sections were quenched with 3% hydrogen peroxide, blocked with 1% bovine serum albumin (BSA), then incubated with specific primary antibody at appropriate dilution (as indicated in Table 1 ) overnight, followed by incubation with HRP-conjugated secondary antibody for 1 h. DAB was used as the chromogenic agent, and hematoxylin was used for nuclei counterstaining.
Immunofluorescence staining. Normal skin and hypertrophic scar tissue sections or fibroblasts were fixed with 4% paraformaldehyde for 10 min, permeabilized with Triton X-100 for 10 min, and blocked with 1% BSA for 1 h at room temperature. Cells were then incubated with specific anti-target protein antibody at 4 °C overnight, followed by incubation with Alexa Fluor ® 488-(green) and/or 555-(red) conjugated secondary antibody (Invitrogen, Carlsbad, CA) for 1 h. DAPI was used for nuclear staining. Images were digitally captured by the FSX100 Bio Imaging Navigator (Olympus, Tokyo, Japan) and analyzed by Image-Pro Plus 6.0 system (Media Cybernetics, Silver Spring, MD).
Construction of mutant FAK and Src mammalian expression vectors.
The full-length coding sequences of wild-type human FAK (GenBank accession no. L13616.1) and Src (GenBank accession no. NM_005417.4), including start and stop codons, were amplified from human hypertrophic scar-derived fibroblast cDNA by PCR using primers listed in Table 2 , and they were individually cloned into the KpnI/XhoI sites of the pcDNA3.1(+) Mammalian Expression Vector (Invitrogen). The mutation of FAK-Tyr 407 or Src-Tyr 529 to phenylalanine (Phe) or glutamic acid (Glu), respectively, was performed by three-step mutagenic PCR 29 , using the wild-type FAK or Src construct as the template. Each desired mutation was introduced by the amplification of two overlapping portions of FAK or Src using two primer pairs (a mutagenic primer paired with a flanking primer with the opposite orientation; Table 2 ). The two PCR products were then fused together by overlap extension 29 , from which the full-length cDNA was amplified with primers listed in Table 2 . The cDNA encoding the full-length FAK, Src, or their corresponding mutant FAK Y407F or Src Y529E was individually cloned into pcDNA3.1(+) Mammalian Expression Vector. All sequences were verified by direct DNA sequencing to confirm the full-length and mutant cDNA constructs. For the transfection into hypertrophic scar-derived fibroblasts, plasmid DNA was prepared with a HiSpeed Plasmid Midi Kit (Qiagen, Hilden, Germany).
Overexpression of wild-type and mutant FAK and Src in hypertrophic scar fibroblast cultures.
Hypertrophic scar fibroblasts were isolated from the dermal portion of scar tissues and plated in 60-cm 2 dishes. Fibroblasts that cultured between 3 rd to 4 th generation were used in this study. After 24 h-incubation, cells were transfected with: ① empty vector group: 5 μ g pcDNA3.1(+); ② pcDNA3.1(+)/FAK group: 2.5 μ g pcDNA3.1(+)/FAK + 2.5 μ g pcDNA3.1(+); ③ pcDNA3.1(+)/FAK Y407F group: 2.5 μ g pcDNA3.1(+)/FAK Y407F + 2.5 μ g pcDNA3.1(+); ④ pcDNA3.1(+)/Src group: 2.5 μ g pcDNA3.1(+)/Src + 2.5 μ g pcDNA3.1(+); ⑤ pcDNA3.1(+)/Src Y529E group: 2.5 μ g pcDNA3.1(+)/Src Y529E + 2.5 μ g pcDNA3.1(+); or ⑥ [pcDNA3.1(+)/ FAK Y407F + pcDNA3.1(+)/Src Y529E] group: 2.5 μ g pcDNA3.1(+)/FAK Y407F + 2.5 μ g pcDNA3.1(+)/Src Y529E, by using Lipofectamine 2000 Transfection Reagent (Invitrogen). Western blot analysis was carried out after an additional 72 h.
Ex vivo tissue culture of hypertrophic scar. The ex vivo tissue culture of hypertrophic scar was performed as described previously 30 . Briefly, the scar tissue was cut into 10 × 10 mm block, and then transfected with: ① empty vector group: 20 μ g pcDNA3.1(+); ② pcDNA3.1(+)/FAK Y407F group: 10 μ g pcDNA3.1(+)/ FAK Y407F + 10 μ g pcDNA3.1(+); ③ pcDNA3.1(+)/Src Y529E group: 10 μ g pcDNA3.1(+)/Src Y529E + 10 μ g pcDNA3.1(+); or ④ [pcDNA3.1(+)/FAK Y407F + pcDNA3.1(+)/Src Y529E] group: 10 μ g pcDNA3.1(+)/ FAK Y407F + 10 μ g pcDNA3.1(+)/Src Y529E, by using Lipofectamine 2000 transfection reagent (Invitrogen) in a 100 μ l volume. This injection was performed intra-dermally into scar tissues. Scar tissues were incubated for 7 days with the culture medium exchanged daily. Tissues were then fixed in 4% paraformaldehyde, followed by routine H&E or Masson trichrome staining according to standard protocols as described earlier 31 . The quantification of ECM and collagen fiber deposition has been analyzed by Image J software.
Statistical analysis. Statistical analysis was performed using SPSS program, version 13.0. In cases n = 4, Mann-Whitney U test was used for paired comparison (Figs 1-4 and 7) , Kruskal-Wallis was used for the comparison among four groups (only selected comparisons were shown) (Fig. 6F,G) . In cases n = 5, after data were tested and satisfied for normal distribution and equal variance, one-way ANOVA was used and followed by NewmanKeuls test for comparisons among six (Fig. 5) or four groups (Fig. 6A-E ) (only selected comparisons were shown). P < 0.05 was considered statistically significant.
